187 related articles for article (PubMed ID: 33926244)
21. Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: A meta-analysis of 31 randomized controlled trials following the PRISMA guidelines.
Xiao Z; Wang C; Zhou M; Hu S; Jiang Y; Huang X; Li N; Feng J; Tang F; Chen X; Ding J; Chen L; Wang Y; Li X
J Ethnopharmacol; 2019 Jan; 228():110-122. PubMed ID: 30243827
[TBL] [Abstract][Full Text] [Related]
22. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD
Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732
[No Abstract] [Full Text] [Related]
23. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.
Gao G; Ren S; Li A; Xu J; Xu Q; Su C; Guo J; Deng Q; Zhou C
Int J Cancer; 2012 Sep; 131(5):E822-9. PubMed ID: 22161771
[TBL] [Abstract][Full Text] [Related]
24. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials.
Li D; Yao L; Xu L; Li W; Che Y
Medicine (Baltimore); 2022 Dec; 101(48):e32164. PubMed ID: 36482605
[TBL] [Abstract][Full Text] [Related]
26. Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis.
Xu C; Zhou Q; Wu YL
J Hematol Oncol; 2012 Oct; 5():62. PubMed ID: 23050865
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
Yi L; Fan J; Qian R; Luo P; Zhang J
Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
[TBL] [Abstract][Full Text] [Related]
28. Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials.
Zhang SL; Yi XF; Huang LT; Sun L; Ma JT; Han CB
BMC Cancer; 2023 Aug; 23(1):719. PubMed ID: 37528390
[TBL] [Abstract][Full Text] [Related]
29. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.
Liu HB; Wu Y; Lv TF; Yao YW; Xiao YY; Yuan DM; Song Y
PLoS One; 2013; 8(1):e55128. PubMed ID: 23383079
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
Zhao P; Zhen H; Zhao H; Zhao L; Cao B
BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies.
Li L; Huang Q; Sun J; Yan F; Wei W; Li Z; Liu L; Deng J
Acta Oncol; 2022 Nov; 61(11):1347-1353. PubMed ID: 36240432
[TBL] [Abstract][Full Text] [Related]
32. The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials.
Wang BC; Zhang WX; Kuang BH; Lin GH
PLoS One; 2022; 17(10):e0275919. PubMed ID: 36215289
[TBL] [Abstract][Full Text] [Related]
33. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
34. Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.
Yan H; Li Q; Wang W; Zhen H; Cao B
Sci Rep; 2015 Oct; 5():15355. PubMed ID: 26481697
[TBL] [Abstract][Full Text] [Related]
35. A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.
Cheng H; Li XJ; Wang XJ; Chen ZW; Wang RQ; Zhong HC; Wu TC; Cao QD
Lung Cancer; 2019 Nov; 137():7-13. PubMed ID: 31520922
[TBL] [Abstract][Full Text] [Related]
36. The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials.
Li G; Gao S; Sheng Z; Li B
Chemotherapy; 2016; 61(4):179-89. PubMed ID: 26859739
[TBL] [Abstract][Full Text] [Related]
37. The effect of kanglaite injection in combination with gefitinib versus gefitinib alone in patients with nonsmall cell lung cancer: A meta-analysis.
Hailang H; Jiping Z; Ailing C; Xianmei Z
J Cancer Res Ther; 2020; 16(4):745-751. PubMed ID: 32930113
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study.
Yu Y; Wang Y; Wu L; Xu X; Zhou H; Wang Q; Zhou J
Medicine (Baltimore); 2021 Feb; 100(5):e23712. PubMed ID: 33592829
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Fan Y; Huang ZY; Yu HF; Luo LH
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
[TBL] [Abstract][Full Text] [Related]
40. Effect of osimertinib in treating patients with first-generation EGFR-TKI-resistant advanced non-small cell lung cancer and prognostic analysis.
Yang Y; Guo Y; Wang R; Li J; Zhu H; Guo RTW
J BUON; 2021; 26(1):51-57. PubMed ID: 33721431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
